Good Dividend Potential for AbbVie in a Tough Landscape
The narrow-moat firm is undervalued and well-positioned with its dividend.
Damien Conover: Today we're talking about AbbVie. AbbVie is a stock that we think is both undervalued and well positioned with its dividend. Right now, the dividend yield is close to 5%, and in a landscape where it's difficult to get yield, we think AbbVie's yield is both secure and has potential for some modest growth over the next few years.
When we think about AbbVie, it's a stock that is trading from a price/earnings basis on a very low metric. It's close to 10 times earnings. And we think it's very secure with its earnings growth over the next three years. But the main reason why it's trading so low is it does have a massive patent loss coming up. In 2024 we think the Humira patent loss will put a lot of pressure on earnings, but from a dividend perspective, we still think AbbVie will be able to support its dividend in the 2024 time period.
Damien Conover does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.